Search
forLearn
5 / 801 resultslearn Tara Tree
learn Tapyadi
learn tangerine extract
learn TeraBond™ (Actera)
Research
5 / 1000+ results
research Novel shampoo reduces hair shedding by contracting the arrector pili muscle via the trace amine‐associated receptor
New shampoo with tyramine hydrochloride reduces hair loss by making a small muscle in the hair follicle contract.
research 50579 Novel Cosmetic Formulation Rapidly Reduces Hair Shedding
The new hair treatment significantly reduces hair shedding safely.
research A Novel Cosmetic Formulation That Rapidly Reduces Hair Shedding in Females
The new hair product quickly reduces hair shedding in women.
research Argan (Argania Spinosa) press cake extract enhances cell proliferation and prevents oxidative stress and inflammation of human dermal papilla cells
Argan press cake extract might help grow hair and protect hair cells from damage and inflammation.
research A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly l-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from
Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
Community Join
5 / 1000+ resultscommunity GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.